GlassScriptPhysician profile
Robert A Zaloom
NPI 1437151016
$1,657.79
in general payments reported to CMS, 2019-2025
19 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.98 · 2020: $15.58 · 2022: $152 · 2023: $299 · 2024: $666 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,460.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $278.93 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $262.70 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $236.01 | 2023-2025 | Verquvo, Capvaxive |
| Abbott Laboratories | $172.70 | 2024-2025 | Cardiomems |
| Pfizer INC. | $152.03 | 2023-2025 | |
| Artivion, INC. | $117.15 | 2024 | On-X Aortic Heart Valve With Conform-X Sewing Ring and Extended Holder, Bioglue Surgical Adhesive, Cryovalve Sg Pulmonary Human Heart Valve |
| E.R. Squibb & Sons, L.L.C. | $78.13 | 2022-2025 | Camzyos |
| Esperion Therapeutics, INC. | $50.86 | 2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $50.52 | 2022 | |
| Scpharmaceuticals INC. | $45.27 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $38.45 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.57 | 2019-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $30.15 | 2024 | |
| Alnylam Pharmaceuticals INC. | $24.98 | 2024 | Amvuttra |
| Bridgebio Pharma, INC. | $20.89 | 2025 | Attruby |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endotronix, INC. | $19.38 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $17.70 | 2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $15.55 | 2024 | |
| Tactile Systems Technology INC | $14.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Zaloom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.